We are seeing patients in-person and through Video Visits. Learn more about how we’re keeping you safe and please review our updated visitor policy. Please also consider supporting Weill Cornell Medicine’s efforts to support our front-line workers.
Sandra and Edward Meyer Cancer Center

Warning message

The subscription service is currently unavailable. Please try again later.

You are here


IMMU-132 in patients with urothelial carcinoma

Tuesday, May 31, 2016

Scott T. Tagawa, M.D., M.S., spoke with OncLive about the antibody-drug conjugate IMMU-132 for the treatment of patients with metastatic platinum-resistant urothelial cancer.

IMMU-132 is an anti–TROP-2 antibody-drug conjugate comprised of SN-38. Regarding safety, the agent is not as toxic compared with other antibody-drug conjugates, Tagawa explains.

In a phase I/II study, grade 3 neutropenia was observed in patients who received IMMU-132, but grade 1/2 diarrhea was one of the most common adverse events. Preliminary findings demonstrate a median progression-free survival of 8.1 months with 50% maturity, and a median overall survival of 10.8 months, with 79% of patients still alive.